As GSK, Aurinia heat up the lupus nephritis category, analyst gauges doctors' first impressions

The lupus nephritis category is sporting a first-ever brand battle—two new-to-category drugs with very different profiles and marketing strategies.

GlaxoSmithKline’s Benlysta, the tried-and-true drug already approved to treat systemic lupus, nabbed its lupus nephritis indication in December, while upstart Aurinia snagged its first-ever drug approval with Lupkynis' FDA nod one month later.